Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 2/20 | 0.42 |
| ▸ | EIF4E | P06730 | 3/20 | 0.37 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.36 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.36 |
| ▸ | HINT1 | P49773 | 1/20 | 0.35 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.33 |
| ▸ | FUT6 | P51993 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3146413 | 0.83 | P2RY2 (0.45) | PNPP2RY2P2RY4P2RY6 | |
| SCHEMBL3138273 | 0.83 | HPRT1 (0.39) | PNPEIF4EP2RY2P2RY4 | |
| SCHEMBL3141537 | 0.81 | P2RY2 (0.47) | P2RY2P2RY4P2RY6 | |
| SCHEMBL15468709 | 0.67 | HINT1 (0.53) | HINT1FUT6 | |
| SCHEMBL15468734 | 0.67 | HINT1 (0.53) | HINT1FUT6 | |
| SCHEMBL13522448 | 0.67 | HINT1 (0.53) | HINT1FUT6 | |
| SCHEMBL15788429 | 0.67 | HINT1 (0.53) | HINT1FUT6 | |
| SCHEMBL13522424 | 0.67 | HINT1 (0.53) | HINT1FUT6 | |
| SCHEMBL18744143 | 0.67 | HINT1 (0.53) | HINT1FUT6 | |
| SCHEMBL6906442 | 0.66 | P2RY2 (0.48) | P2RY2P2RY4P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307434-B1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS INC (US) | 2014-02-12 | — | — | EP | disclosed |
| EP-2476690-A1 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX Pharmaceuticals, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| US-20100003217-A1 | Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections | CRETTON-SCOTT ERIKA | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003217-A1 | Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections | HAVCR2, PYGL, GOT1 | PNP 17/4885EIF4E 1683/4885P2RY2 2250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.